CZO:CC News and Press, Ceapro Inc. From 11/22/23

Platinum Group Metals Ltd. (PTM:CA) is expected to report for quarter end 2023-08-31 C-COM Satellite Systems Inc. (CMI:CA) is expected to report for Q1 2024 Skylight Health Group Inc. (SLHG.H:CA) is expected to report for Q3 2023 Contagious Gaming Inc. (CNS:CA) is expected to report f...

Mapath Capital Corp. (MPTH.H:CA) is expected to report for Q1 2024 Essential Energy Services Ltd. (ESN:CA) is expected to report for Q1 2024 Next Hydrogen Solutions Inc. (NXH:CA) is expected to report for Q1 2024 Osisko Mining Inc. (OSK:CA) is expected to report $-0.02 for Q3 2023 ...

Nova Cannabis Inc. (NOVC:CA) is expected to report for Q3 2023 Giyani Metals Corp. (EMM:CA) is expected to report for Q2 2024 Petrus Resources Ltd. (PRQ:CA) is expected to report $0.03 for Q3 2023 Alaris Equity Partners Income Trust (AD.UN:CA) is expected to report $0.42 for Q3 2023 ...

PGX processing unit with a 10X (100 L) vessel capacity to be installed and tested at NATEX pilot testing facility in Austria Yeast beta glucan (YBG) to be the first bio active to be processed at this location EDMONTON, Alberta, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. ...

- $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace reorganization - Ended the quarter with $11.3 million in cash allowing funding fo...

– Exclusive agreement extended from 3 to 5 years until December 31, 2026 – Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market – Offering of new preservative free dry prod...

– New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products – EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the ...

EDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic ind...

EDMONTON, Alberta, June 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic...

– Q1 2023 sales of $3,500,000 vs $6,172,000 in Q1 2022 – Ended the quarter with $12.6 million in cash allowing funding for planned pipeline development EDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: ...